Investigational drug · Phase 3
Soquelitinib
Also called: CPI-818
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
5
Any phase or sponsor naming "Soquelitinib"
First trial start
2024
Oct 2, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Soquelitinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Atopic Dermatitis
- Atopic Dermatitis Eczema
- Eczema
- Eczema, Atopic
- Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Angioimmunoblastic T-cell Lymphoma
- Follicular T-Cell Lymphoma
- Nodal Peripheral T-Cell Lymphoma With TFH Phenotype
- Systemic Anaplastic Large Cell Lymphoma
- Lymphoma, T-Cell, Peripheral
Approved drugs for the same conditions: Atopic dermatitis (eczema) · Hematology and blood cancers · Immunology and inflammation · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "Soquelitinib" as an intervention, largest first.
- Study to Evaluate Soquelitinib in Participants With Moderate to Severe ADPivotal-lookingRecruiting
Corvus Pharmaceuticals, Inc.Industry
NCT07441395 · 200 participants (planned) · Start Feb 2026 · Primary completion Jun 2027
Drug: Soquelitinib; Placebo · For: Atopic Dermatitis; Atopic Dermatitis Eczema; Eczema and 1 more
Sites: South San Francisco, California
- Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell LymphomaPivotal-lookingRecruiting
Corvus Pharmaceuticals, Inc.Industry
NCT06561048 · 150 participants (planned) · Start Oct 2, 2024 · Primary completion Nov 2027
Drug: Soquelitinib; Belinostat and 1 more · For: Peripheral T-Cell Lymphoma, Not Otherwise Specified; Angioimmunoblastic T-cell Lymphoma; Follicular T-Cell Lymphoma and 4 more
Sites: Duarte, California; Irvine, California; San Francisco, California · 37 sites in all
Corvus Pharmaceuticals, Inc.Industry
NCT06345404 · 82 participants · Start Apr 16, 2024 · Primary completion Jan 28, 2026
Drug: Soquelitinib; Placebo · For: Atopic Dermatitis
Sites: Birmingham, Alabama; Tucson, Arizona; North Little Rock, Arkansas · 16 sites in all
Corvus Pharmaceuticals, Inc.Industry
NCT07828860 · 25 participants (planned) · Start Sep 17, 2026 · Primary completion Dec 2027
Drug: Soquelitinib · For: Hidradenitis Suppurativa (HS)
Sites: West Lafayette, Indiana; Bowling Green, Kentucky; Owensboro, Kentucky · 11 sites in all
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT06730126 · 15 participants (planned) · Start Mar 10, 2025 · Primary completion Dec 1, 2026
Drug: Soquelitinib · For: Autoimmune Lymphoproliferative Syndrome
Sites: Bethesda, Maryland; Philadelphia, Pennsylvania; Houston, Texas
Newest research
PubMed records naming it or its code names, newest first.
- Phase 1 Trial with Soquelitinib, a Selective ITK Inhibitor for Treatment of Relapsed/Refractory T Cell Lymphomas.
Miller RA, Ding N, Reneau JC, et al. · Blood 2026
- Phosphotyrosine proteomics reveals novel Zap70 and Itk pathway targets downstream of TCR and CAR in Jurkat T cells.
Callahan A, Trychanh SS, Ro T, et al. · Sci Rep 2026
- ITK-targeted immune remodeling enhanced the efficacy of anti-CD19 CAR-T cell therapy.
Li Z, Lv L, Yao X, et al. · Cell Death Discov 2026
- Phosphoproteomic analysis of successive Jurkat CD19-CAR generations reveals TCRζ-driven signalling.
Callahan A, Puterbaugh RZ, Ro T, et al. · Cell Signal 2026
- Soquelitinib inhibition of IL-2-inducible T cell kinase ameliorates lung damage in murine models of systemic sclerosis.
Boleto G, Cauvet A, Guignabert C, et al. · Arthritis Res Ther 2025
- Inclusion of the ζ-chain drives phosphotyrosine signalling in CD19-CAR T cells.
Callahan A, Puterbaugh RZ, Ro T, et al. · bioRxiv 2025
Also in development for Atopic Dermatitis
- AfimkibartRO7790121, RVT-3101Phase 312 trials
Roche (Genentech) · Moderately to Severely Active Ulcerative Colitis, Moderately to Severely Active Crohns Disease, Atopic Dermatitis
- CM512Phase 39 trials
Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma
- LutikizumabABT-981Phase 38 trials
AbbVie · Hidradenitis Suppurativa, Atopic Dermatitis, Rheumatoid Arthritis
- PF-07275315tilrekimigPhase 38 trials
Pfizer · Atopic Dermatitis, Asthma, Moderate to Severe Chronic Obstructive Pulmonary Disease
- barzolvolimabCDX-0159Phase 37 trials
Celldex Therapeutics · Chronic Spontaneous Urticaria, Chronic Inducible Urticaria, Cold Urticaria
- MG-K10Humanized Monoclonal AntibodyPhase 36 trials
Shanghai Mabgeek Biotech.Co.Ltd · Dermatitis, Atopic, Chronic Urticaria, Idiopathic, Atopic Dermatitis
- CM310Phase 35 trials
Keymed Biosciences Co.Ltd · Atopic Dermatitis, Moderate to Severe Asthma, Chronic Obstructive Pulmonary Disease
- VC005Phase 35 trials
Jiangsu vcare pharmaceutical technology co., LTD · Non-segmental Vitiligo, Non-Segmental Vitiligo, Atopic Dermatitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.